BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 30499246)

  • 21. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.
    Marchesoni A; Olivieri I; Salvarani C; Pipitone N; D'Angelo S; Mathieu A; Cauli A; Punzi L; Ramonda R; Scarpa R; Maccarone M; Lubrano E
    Clin Exp Rheumatol; 2017; 35(6):991-1010. PubMed ID: 29185959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
    Mourad A; Gniadecki R
    J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
    Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
    Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
    Mease PJ; Armstrong AW
    Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.
    Baum EW; Schwartzman S
    Semin Cutan Med Surg; 2018 Dec; 37(6S):S125-S134. PubMed ID: 30605493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological and synthetic target DMARDs in psoriatic arthritis.
    Silvagni E; Bortoluzzi A; Ciancio G; Govoni M
    Pharmacol Res; 2019 Nov; 149():104473. PubMed ID: 31585178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
    Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
    Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
    BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis.
    Salvarani C; Olivieri I; Pipitone N; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2006; 24(1):70-8. PubMed ID: 16539822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
    Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
    Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
    Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
    Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
    Ward MM; Deodhar A; Gensler LS; Dubreuil M; Yu D; Khan MA; Haroon N; Borenstein D; Wang R; Biehl A; Fang MA; Louie G; Majithia V; Ng B; Bigham R; Pianin M; Shah AA; Sullivan N; Turgunbaev M; Oristaglio J; Turner A; Maksymowych WP; Caplan L
    Arthritis Rheumatol; 2019 Oct; 71(10):1599-1613. PubMed ID: 31436036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
    McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis].
    Fernández Sueiro JL; Juanola Roura X; Cañete Crespillo Jde D; Torre Alonso JC; García de Vicuña R; Queiro Silva R; Ariza Ariza R; Batlle Gualda E; Loza Santamaría E;
    Reumatol Clin; 2011; 7(3):179-88. PubMed ID: 21794810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
    Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
    Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.